Drug intelligence / Profile preview

AON-PP23

Development stage: Preclinical
Lead developer: Astrion
Modality: Small Molecules

Overview

AON-PP23 is a preclinical-stage small molecule candidate being developed by Astrion for the treatment of Parkinson's disease. The drug is designed to target alpha-synuclein aggregates, which are a hallmark of Parkinson's pathology and contribute to neurodegeneration. By targeting these protein aggregates, AON-PP23 aims to modify the course of the disease rather than just treating symptoms. As of 2024, the program is in the non-clinical stage, with the developer targeting an Investigational New Drug (IND) filing in the fourth quarter of 2028.

Targets

aggregated α-syn (Alpha-synuclein (α-syn))

Beyond the preview

Go deeper on AON-PP23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AON-PP23.

Explore the full profile